Journal Article
. 2010 Sep;10().
doi: 10.1186/1471-2407-10-507.

Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

Yoon-La Choi 1 Ensel Oh  Sarah Park  Yeonju Kim  Yeon-Hee Park  Kyoung Song  Eun Yoon Cho  Yun-Chul Hong  Jong Sun Choi  Jeong Eon Lee  Jung Han Kim  Seok Jin Nam  Young-Hyuck Im  Jung-Hyun Yang  Young Kee Shin  
  • PMID: 20860845
  •     28 References
  •     25 citations


Background: Triple-negative breast cancers (TNBCs) and basal-like breast cancers (BLBCs) are known as poor outcome subtypes with a lack of targeted therapy. Previous studies have shown conflicting results regarding the difference of prognostic significance between TNBCs and BLBCs. In this study, we aimed to characterize the prognostic features of TNBCs, in view of BLBCs and quintuple-negative breast cancers (QNBC/5NPs).

Methods: Using tissue microarray-based immunohistochemical analysis, we categorized 951 primary breast cancers into four or five subtypes according to the expression of ER, PR, HER2, and basal markers (CK5/6, EGFR).

Results: The results of this study showed that both TNBCs and BLBCs were associated with high histological and/or nuclear grades. When the TNBCs are divided into two subtypes by the presence of basal markers, the clinicopathologic characteristics of TNBCs were mainly maintained in the BLBCs. The 5-subgrouping was the better prediction model for both disease free and overall survival in breast cancers than the 4-subgrouping. After multivariate analysis of TNBCs, the BLBCs did not have a worse prognosis than the QNBC/5NPs. Interestingly, the patients with BLBCs showed significant adjuvant chemotherapy benefit. In addition, QNBC/5NPs comprised about 6~8% of breast cancers in publicly available breast cancer datasets

Conclusion: The QNBC/5NP subtype is a worse prognostic subgroup of TNBCs, especially in higher stage and this result may be related to adjuvant chemotherapy benefit of BLBCs, calling for caution in the identification of subgroups of patients for therapeutic classification.

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.
Marc Tischkowitz, Jean-Sébastien Brunet, +5 authors, William D Foulkes.
BMC Cancer, 2007 Jul 26; 7. PMID: 17650314    Free PMC article.
Highly Cited.
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, +7 authors, Charles M Perou.
Clin Cancer Res, 2007 Apr 18; 13(8). PMID: 17438091
Highly Cited.
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials.
R Conforti, T Boulet, +9 authors, F Andre.
Ann Oncol, 2007 May 23; 18(9). PMID: 17515403
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
Bas Kreike, Marieke van Kouwenhove, +4 authors, Marc J van de Vijver.
Breast Cancer Res, 2007 Oct 04; 9(5). PMID: 17910759    Free PMC article.
Highly Cited.
Are triple-negative and basal-like breast cancer synonymous?
Emad Rakha, Ian Ellis, Jorge Reis-Filho.
Clin Cancer Res, 2008 Jan 29; 14(2). PMID: 18223240
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Maggie C U Cheang, David Voduc, +5 authors, Torsten O Nielsen.
Clin Cancer Res, 2008 Mar 05; 14(5). PMID: 18316557
Highly Cited.
How basal are triple-negative breast cancers?
François Bertucci, Pascal Finetti, +4 authors, Daniel Birnbaum.
Int J Cancer, 2008 Apr 10; 123(1). PMID: 18398844
Highly Cited.
Basal-like breast cancer: a critical review.
Emad A Rakha, Jorge S Reis-Filho, Ian O Ellis.
J Clin Oncol, 2008 May 20; 26(15). PMID: 18487574
Highly Cited. Review.
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.
David S P Tan, Caterina Marchió, +4 authors, Jorge S Reis-Filho.
Breast Cancer Res Treat, 2007 Oct 09; 111(1). PMID: 17922188
Is triple negative a prognostic factor in breast cancer?
Reiki Nishimura, Nobuyuki Arima.
Breast Cancer, 2008 Mar 29; 15(4). PMID: 18369692
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Jiyoung Rhee, Sae-Won Han, +7 authors, Tae-You Kim.
BMC Cancer, 2008 Oct 25; 8. PMID: 18947390    Free PMC article.
What is triple-negative breast cancer?
William J Irvin, Lisa A Carey.
Eur J Cancer, 2008 Nov 15; 44(18). PMID: 19008097
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Emad A Rakha, Somaia E Elsheikh, +12 authors, Ian O Ellis.
Clin Cancer Res, 2009 Mar 26; 15(7). PMID: 19318481
Highly Cited.
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Daniel P Silver, Andrea L Richardson, +19 authors, Judy E Garber.
J Clin Oncol, 2010 Jan 27; 28(7). PMID: 20100965    Free PMC article.
Highly Cited.
The phenotypic spectrum of basal-like breast cancers: a critical appraisal.
Oluwole Fadare, Fattaneh A Tavassoli.
Adv Anat Pathol, 2007 Aug 25; 14(5). PMID: 17717437
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, +13 authors, David Botstein.
Proc Natl Acad Sci U S A, 2003 Jun 28; 100(14). PMID: 12829800    Free PMC article.
Highly Cited.
Clinical characteristics of breast cancer patients in Korea in 2000.
Sei Hyun Ahn, Korean Breast Cancer Society.
Arch Surg, 2004 Jan 14; 139(1). PMID: 14718270
HER-2 testing in breast cancer using parallel tissue-based methods.
Hadi Yaziji, Lynn C Goldstein, +6 authors, Allen M Gown.
JAMA, 2004 Apr 29; 291(16). PMID: 15113815
Validation of tissue microarray technology in ovarian carcinoma.
Daniel G Rosen, Xuelin Huang, +3 authors, Jinsong Liu.
Mod Pathol, 2004 Apr 10; 17(7). PMID: 15073602
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Torsten O Nielsen, Forrest D Hsu, +13 authors, Charles M Perou.
Clin Cancer Res, 2004 Aug 26; 10(16). PMID: 15328174
Highly Cited.
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.
J M Harvey, G M Clark, C K Osborne, D C Allred.
J Clin Oncol, 1999 May 20; 17(5). PMID: 10334533
Highly Cited.
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
Yixin Wang, Jan G M Klijn, +11 authors, John A Foekens.
Lancet, 2005 Feb 22; 365(9460). PMID: 15721472
Highly Cited.
Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Roman Rouzier, Charles M Perou, +13 authors, Lajos Pusztai.
Clin Cancer Res, 2005 Aug 24; 11(16). PMID: 16115903
Highly Cited.
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, +14 authors, Robert C Millikan.
JAMA, 2006 Jun 08; 295(21). PMID: 16757721
Highly Cited.
Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Mi-Jung Kim, Jae Y Ro, +3 authors, Gyungyub Gong.
Hum Pathol, 2006 Aug 30; 37(9). PMID: 16938528
Highly Cited.
Prognostic markers in triple-negative breast cancer.
Emad A Rakha, Maysa E El-Sayed, +3 authors, Ian O Ellis.
Cancer, 2006 Dec 06; 109(1). PMID: 17146782
Highly Cited.
The characterization of cell line crl-2335 as a Basal-like breast carcinoma model.
Lori A Hill Neves, Lishann Ingram, Melissa B Davis.
Breast Cancer (Auckl), 2011 May 24; 5. PMID: 21603256    Free PMC article.
Management options in triple-negative breast cancer.
Christina A Minami, Debra U Chung, Helena R Chang.
Breast Cancer (Auckl), 2011 Aug 25; 5. PMID: 21863131    Free PMC article.
Clinical significance of CD151 overexpression in subtypes of invasive breast cancer.
M J Kwon, S Park, +9 authors, Y-L Choi.
Br J Cancer, 2012 Feb 02; 106(5). PMID: 22294188    Free PMC article.
Significance of histomorphology of early triple-negative breast cancer.
Gábor Rubovszky, Zsolt Horváth, +2 authors, Miklós Kásler.
Pathol Oncol Res, 2012 Mar 15; 18(4). PMID: 22415664
Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity.
Melissa B Davis, Xinyu Liu, +4 authors, Olufunmilayo I Olopade.
Mol Cancer, 2013 May 15; 12(1). PMID: 23663560    Free PMC article.
Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer.
Fares Al-Ejeh, Mariska Miranda, +10 authors, Kum Kum Khanna.
Oncotarget, 2014 Apr 26; 5(10). PMID: 24762669    Free PMC article.
Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts.
Binafsha M Syed, Andrew R Green, +3 authors, Kwok-Leung Cheung.
PLoS One, 2014 Jul 08; 9(7). PMID: 24999743    Free PMC article.
Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.
Jung Eun Choi, Su Hwan Kang, Soo Jung Lee, Young Kyung Bae.
Tumour Biol, 2014 Sep 03; 35(12). PMID: 25179840
The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
Anna Bergamaschi, Zeynep Madak-Erdogan, +3 authors, Benita S Katzenellenbogen.
Breast Cancer Res, 2014 Sep 13; 16(5). PMID: 25213081    Free PMC article.
Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
Hyun Ae Jung, Yeon Hee Park, +10 authors, Young-Hyuck Im.
Tumour Biol, 2014 Oct 20; 36(2). PMID: 25326808
A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer.
H J Kim, S-H Kim, +2 authors, J H Kim.
Oncogene, 2014 Nov 25; 34(34). PMID: 25417701
CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer.
Mi Jeong Kwon, Jinil Han, +7 authors, Young Kee Shin.
PLoS One, 2015 Oct 09; 10(10). PMID: 26444008    Free PMC article.
Comparison of Accuracy of Whole-Exome Sequencing with Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tissue Samples.
Ensel Oh, Yoon-La Choi, +5 authors, Young Kee Shin.
PLoS One, 2015 Dec 08; 10(12). PMID: 26641479    Free PMC article.
Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers.
Yan-Xi Liu, Ke-Ren Wang, +3 authors, Wan Wang.
Oncol Lett, 2016 Jul 23; 12(2). PMID: 27446423    Free PMC article.
Breast cancer molecular subtypes: from TNBC to QNBC.
Jane Date C Hon, Baljit Singh, +7 authors, Peng Lee.
Am J Cancer Res, 2016 Oct 12; 6(9). PMID: 27725895    Free PMC article.
A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2- early breast cancer.
Gyungyub Gong, Mi Jeong Kwon, +15 authors, Young Kee Shin.
Sci Rep, 2017 Mar 30; 7. PMID: 28350001    Free PMC article.
EGFR expression is associated with cytoplasmic staining of CXCR4 and predicts poor prognosis in triple-negative breast carcinomas.
Rong-Hui Li, Wen-He Huang, +2 authors, Guo-Jun Zhang.
Oncol Lett, 2017 Mar 31; 13(2). PMID: 28356948    Free PMC article.
MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
Jinil Han, Yoon-La Choi, +11 authors, Young Kee Shin.
Breast Cancer Res Treat, 2017 Apr 15; 164(1). PMID: 28409241    Free PMC article.
Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients.
Hae Min Jeong, Ryong Nam Kim, +13 authors, Young Kee Shin.
Oncotarget, 2017 Oct 06; 8(37). PMID: 28977883    Free PMC article.
Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.
Yu Jin Kim, Minjung Sung, +4 authors, Yoon-La Choi.
Cancer Biol Ther, 2018 Jan 16; 19(4). PMID: 29333926    Free PMC article.
miRNA-135b Contributes to Triple Negative Breast Cancer Molecular Heterogeneity: Different Expression Profile in Basal-like Versus non-Basal-like Phenotypes.
Paolo Uva, Paolo Cossu-Rocca, +9 authors, Maria Rosaria De Miglio.
Int J Med Sci, 2018 May 05; 15(6). PMID: 29725243    Free PMC article.
BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer.
Mi Jeong Kwon, Sae Byul Lee, +8 authors, Young Kee Shin.
PLoS One, 2018 Nov 22; 13(11). PMID: 30462685    Free PMC article.
High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.
Hyelin Na, Jinil Han, +4 authors, Mi-Ock Lee.
Breast Cancer Res, 2019 Nov 30; 21(1). PMID: 31779659    Free PMC article.
Imaging Biomarkers as Predictors for Breast Cancer Death.
Wendy Yi-Ying Wu, Laszlo Tabar, +10 authors, Hsiu-Hsi Chen.
J Oncol, 2019 May 17; 2019. PMID: 31093281    Free PMC article.
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Mi Jeong Kwon, Jeong Eon Lee, +12 authors, Young Kee Shin.
Front Oncol, 2019 Aug 14; 9. PMID: 31404265    Free PMC article.